***Background.*** Ceftaroline fosamil (CPT) is a broad-spectrum cephalosporin prodrug with potent activity against pathogens causing community-acquired (CA) RTI, including ceftriaxone (CRO)-resistant (R) *Streptococcus pneumoniae* (SPN) and methicillin-R *Staphylococcus aureus* (MRSA). We evaluated the potency and spectrum CPT and several comparators tested against CA-RTI pathogens.

***Methods.*** 4,533 unique patient isolates were collected from 149 USA medical centers during 2013. The collection includes 3,099 *S. pneumoniae* (SPN; 6.5% CRO-non-S), 931 *Haemphilus influenzae* (HI; 23.8% β-lactamase-positive \[BL + \]), 99 *H. parainfluenzae* (HPAR) and 404 *Moraxella catarrhalis*(MCAT). Susceptibility (S) was tested by CLSI broth microdilution methods against CPT and other antimicrobials used to treat CA-RTI.

***Results.*** CPT (MIC~50/90~, ≤0.015/0.12 µg/mL was eight-fold more potent than CRO (MIC~50/90~, ≤0.06/1 µg/mL) against SPN, and highly active against CRO-non-S SPN strains (n = 201; MIC~90~, 0.25 µg/mL). S rates for SPN were 92.8% for penicillin (MIC, ≤2 µg/mL), 88.5% for amoxicillin/clavulanate, 56.0% for erythromycin, 77.0% for tetracycline and 98.8% for levofloxacin (LEV). CPT was very active against HI (MIC~50/90~, 0.008/0.015 µg/mL), including BL+ strains (CPT MIC~50/90~, 0.015/0.03 µg/mL). S rates for clarithromycin, azithromycin and LEV among HI were 90.3, 99.1 and 99.8%, respectively. CPT was also active against HPAR (MIC~50/90~, 0.008/0.03 µg/mL) and MCAT (MIC~50/90~, 0.06/0.12 µg/mL; table).

                                Cumulative % at ceftaroline MIC (µg/mL) of:                                
  ----------------------------- --------------------------------------------- ------ ------ ------ ------- -------
  *S. pneumoniae* (3,099)       62.5                                          72.3   82.1   96.4   99.6    100.0
   Ceftriaxone-non-S (201)      \--                                           0.5    1      51.2   94.0    100.0
  *H. influenzae* (931)         90.2                                          98.3   99.7   99.9   100.0   \--
   β-lactamase-positive (222)   77.5                                          94.6   98.6   99.5   100.0   \--
  *H. parainfluenzae* (99)      87.9                                          94.9   97.0   99.0   99.0    100.0
  *M. catarrhalis* (404)        10.1                                          33.7   66.3   91.3   99.3    100.0

***Conclusion.*** CPT exhibited high activity against bacterial pathogens from CARTI recently (2013) collected from 149 USA medical centers; all organisms (100.0%) were CPT-S. CPT was particularly active against CRO-non-S SPN. Based on these results, CPT represents a valuable agent for treatment of CA-RTI, including multidrug-R isolates.

***Disclosures.*** **H. S. Sader**, Forest: Grant Investigator, Research grant **D. J. Farrell**, Forest: Grant Investigator, Research grant **R. K. Flamm**, Forest: Grant Investigator, Research grant **R. N. Jones**, Forest: Grant Investigator, Research grant

[^1]: **Session:** 106. Clinical Respiratory Infections

[^2]: Friday, October 10, 2014: 12:30 PM
